Osborne CK - Search Results

1

Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer.

Osborne CK, Schiff R. Osborne CK, et al. Breast. 2003 Dec;12(6):362-7. doi: 10.1016/s0960-9776(03)00137-1. Breast. 2003. PMID: 14659106 Review.

2

Mechanisms of tamoxifen resistance.

Osborne CK, Fuqua SA. Osborne CK, et al. Breast Cancer Res Treat. 1994;32(1):49-55. doi: 10.1007/BF00666205. Breast Cancer Res Treat. 1994. PMID: 7819585 Review.

3

Measurement of steroid hormone receptors in breast cancer patients on tamoxifen.

Encarnación CA, Ciocca DR, McGuire WL, Clark GM, Fuqua SA, Osborne CK. Encarnación CA, et al. Among authors: osborne ck. Breast Cancer Res Treat. 1993;26(3):237-46. doi: 10.1007/BF00665801. Breast Cancer Res Treat. 1993. PMID: 8251648

4

Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes.

Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, Del-Rio AL, Ricote M, Ngo S, Gemsch J, Hilsenbeck SG, Osborne CK, Glass CK, Rosenfeld MG, Rose DW. Lavinsky RM, et al. Among authors: osborne ck. Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):2920-5. doi: 10.1073/pnas.95.6.2920. Proc Natl Acad Sci U S A. 1998. PMID: 9501191 Free PMC article.

5

Statistical analysis of array expression data as applied to the problem of tamoxifen resistance.

Hilsenbeck SG, Friedrichs WE, Schiff R, O'Connell P, Hansen RK, Osborne CK, Fuqua SA. Hilsenbeck SG, et al. Among authors: osborne ck. J Natl Cancer Inst. 1999 Mar 3;91(5):453-9. doi: 10.1093/jnci/91.5.453. J Natl Cancer Inst. 1999. PMID: 10070945

6

Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.

Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, Martino S, Osborne CK. Elledge RM, et al. Among authors: osborne ck. Int J Cancer. 2000 Mar 20;89(2):111-7. Int J Cancer. 2000. PMID: 10754487 Clinical Trial.

7

Selective estrogen receptor modulators: structure, function, and clinical use.

Osborne CK, Zhao H, Fuqua SA. Osborne CK, et al. J Clin Oncol. 2000 Sep;18(17):3172-86. doi: 10.1200/JCO.2000.18.17.3172. J Clin Oncol. 2000. PMID: 10963646 Review.

8

Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo.

Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, Lawrence R, Deneke S, Herrera R, Chamness GC, Fuqua SA, Brown PH, Osborne CK. Schiff R, et al. Among authors: osborne ck. J Natl Cancer Inst. 2000 Dec 6;92(23):1926-34. doi: 10.1093/jnci/92.23.1926. J Natl Cancer Inst. 2000. PMID: 11106684

9

Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth.

Oesterreich S, Zhang P, Guler RL, Sun X, Curran EM, Welshons WV, Osborne CK, Lee AV. Oesterreich S, et al. Among authors: osborne ck. Cancer Res. 2001 Aug 1;61(15):5771-7. Cancer Res. 2001. PMID: 11479214

10

Estrogen receptor: current understanding of its activation and modulation.

Osborne CK, Schiff R, Fuqua SA, Shou J. Osborne CK, et al. Clin Cancer Res. 2001 Dec;7(12 Suppl):4338s-4342s; discussion 4411s-4412s. Clin Cancer Res. 2001. PMID: 11916222 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

376 results

Search Page

Filters